3'-azido-3'-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 428, Issue 1-2, 1999, Pages 41-47

  Olivero, Ofelia A ^a   Parikka, Riitta ^b   Poirier, Miriam C ^a   Vähäkangas, Kirsi ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

AIDS; Placental perfusion; Transplacental carcinogenesis; Zidovudine

Indexed keywords

BUPIVACAINE; LIDOCAINE; ZIDOVUDINE;

CONFERENCE PAPER; DRUG DNA BINDING; DRUG METABOLISM; FETUS; GENOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; PLACENTAL TRANSFER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGIONAL PERFUSION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DNA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MATERNAL-FETAL EXCHANGE; PERFUSION; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED AGENTS;

EID: 0032788624     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00030-7     Document Type: Conference Paper

References (16)

1. Ala-Kokko T.I., Pienimaki P., Herva R., Hollmen A.I., Pelkonen O., Vähäkangas K. Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Pharmacol. Toxicol. 77:1995;142-148.
2. Centers for Disease Control and Prevention Update: AIDS among women - United States, MMWR Morb. Mortal. Wkly. Rep. 44, 1995, 81-84.
3. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J., VanDyke R., Bey M., Shearer W., Jacobson R.L.et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1994;1173-1180. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
4. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., Jones A.B., Rice J.M., Riggs C.W., Logsdon D., Yuspa S.H., Poirier M.C. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 89:1997;1602-1608.
5. T.I. Ala-Kokko, P. Myllynen, K. Vähäkangas, Ex vivo perfusion of human placental cotyledon. Implications for anesthetic pharmacology, Int. J. Obstetric Anesthesia, in press.
6. Boal J.H., Plessinger M., Van Den Reydt C., Miller R.K. Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Toxicol. Appl. Pharmacol. 143:1997;13-21.
7. Schenker S., Johnson R.F., King T.S., Schenken R.S., Henderson G.I. Azidothymidine (zidovudine) transport by the human placenta. Am. J. Med. Sci. 299:1990;16-20.
8. Bawdon R.E., Sobhi S., Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am. J. Obstet. Gynecol. 167:1992;1570-1574.
9. Casey B.M., Bawdon R.E. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 179:1998;758-761.
10. Shafik H.M., Nokta M.A., Pollard R.B. Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients. Antiviral. Res. 16:1991;205-212.
11. Olivero O.A., Beland F.A., Fullerton N.F., Poirier M.C. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′-dideoxythymidine (AZT). Cancer Res. 54:1994;6235-6242.
12. Zhang Z., Diwan B.A., Anderson L.M., Logsdon D., Olivero O.A., Haines D.C., Rice J.M., Yuspa S.H., Poirier M.C. Skin tumorigenesis and K-ras and H-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′,3′-dideoxythymidine (AZT). Mol. Carcinog. 23:1998;45-51.
13. Kind C., Rudin C., Siegrist C.A., Wyler C.A., Biedermann K., Lauper U., Irion O., Schupbach J., Nadal D. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Aids. 12:1998;205-210.
14. Mansergh G., Haddix A.C., Steketee R.W., Nieburg P.I., Hu D.J., Simonds R.J., Rogers M. Cost-effective of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA. 276:1996;139-145.
15. Taneepanichskul S., Sirinavin S., Phuapradit W., Chaturachinda K. Effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission. Aust. N. Z. J. Obstet. Gynaecol. 37:1997;329-331.
16. Culnane M.S., Fowler M.G., Lee S.S., McSherry G., Brady M., O'Donnell K., Mofenson L., Gortmaker S.L., Shapiro D.E., Scott G., Jimenez E., Moore E.C., Diaz C., Flynn P.M., Cunningham B., Oleske J. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J. Am. Med Assoc. 281:1999;151-157.